CancerDrs

Breast Cancer clinical trials in Maine

9 actively recruiting breast cancer trials at 14 sites across Maine.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Maine:
  • Harold Alfond Center for Cancer Care — Augusta, Maine
  • MaineHealth Waldo Hospital — Belfast, Maine
  • MaineHealth Maine Medical Center - Biddeford — Biddeford, Maine
  • Mid Coast Hospital — Brunswick, Maine
  • MaineHealth LincolnHealth Hospital — Damariscotta, Maine
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Maine:
  • Harold Alfond Center for Cancer Care — Augusta, Maine
  • New England Cancer Specialists - Kennebunk — Kennebunk, Maine
  • Penobscot Bay Medical Center — Rockport, Maine
  • MaineHealth Cancer Care and IV Therapy - South Portland — South Portland, Maine
  • New England Cancer Specialists - Topsham — Topsham, Maine
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Maine:
  • Lafayette Family Cancer Center-EMMC — Brewer, Maine
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…

Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in Maine:
  • New England Cancer Specialists — Westbrook, Maine
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Maine:
  • New England Cancer Specialists ( Site 0051) — Westbrook, Maine
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Maine:
  • Clinical Trial Site — Scarborough, Maine
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

ATEMPT 2.0: Adjuvant T-DM1 vs TH

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …

Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in Maine:
  • Eastern Maine Medical Center (Northern Light) — Brewer, Maine
  • New England Cancer Specialists — Scarborough, Maine
View on ClinicalTrials.gov →
NA Recruiting Industry

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk…

Sponsor: Natera, Inc.
NCT ID: NCT07214532
Sites in Maine:
  • New England Cancer Specialists — Westbrook, Maine
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19